Ian W. Flinn, MD, PhD
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TNAuthored Items
Shelbi Burtt BSN, RN, OCN, Jessica Scott, RN, BSN, OCN, Cathy Zhou, MS, Lori Styles, MD, David Arthur, PhD, Bertrand Anz, MD, Ian W. Flinn, MD, PhD
November 2019 Vol 10, No 11
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase, is approved in the US for CLL/SLL treatment, including in combination with obinutuzumab.
Last modified: November 6, 2019